Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001932 · ClinicalTrials.gov registry record
Serotonin Receptors in Seizure Disorders
A clinical trial of Partial Epilepsy, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- 95
- Enrollment target
- 1
- Study location
NCT00001932 is a study of Partial Epilepsy that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 95 participants, below the 507-participant average among 7 other Partial Epilepsy trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00001932, a study of Partial Epilepsy, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients in this study will undergo PET scans (a type of nuclear imaging test) to look for abnormalities in certain brain proteins associated with seizures. Studies in animals have shown that serotonin-a chemical messenger produced by the body-attaches to proteins on brain cells called 5HT1A receptors and changes them in some way that may help control seizures. There is little information on these changes, however. A new compound that is highly sensitive to 5HT1A, will be used in PET imaging to measure the level of activity of these receptors and try to detect abnormalities. Changes in receptor activity may help determine where in the brain the seizures are originating. Additional PET scans will be done to measure the amount of blood flow to the brain and the rate at which the brain uses glucose-a sugar that is the brain's main fuel. Blood flow measurement is used to calculate the distribution of serotonin receptors, and glucose use helps determine how seizures affect brain function. The information gained from the study will be used to try to help guide the patient's therapy and determine if surgery might be beneficial in controlling the patient's seizures.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 1999-06-21 |
| Est. Completion | 2007-08-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001932
The ClinicalTrials.gov registry entry for NCT00001932 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 507-participant average among 7 other Partial Epilepsy trials with a reported enrollment target (81% lower). The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Partial Epilepsy appearing as the primary indexed condition, and to 0 interventions.
NCT00001932 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001932 about?
NCT00001932 is a clinical study titled "Serotonin Receptors in Seizure Disorders". Patients in this study will undergo PET scans (a type of nuclear imaging test) to look for abnormalities in certain brain proteins associated with seizures. Studies in animals have shown that serotonin-a chemical messenger produced by the body-attaches to proteins on brain cells called 5HT1A recept...
What is the current status of trial NCT00001932?
This trial is currently completed. The enrollment target is 95 participants. The study started on 1999-06-21. Estimated completion is 2007-08-15.
What conditions does trial NCT00001932 study?
This clinical trial studies the following conditions: Partial Epilepsy.
Who is sponsoring clinical trial NCT00001932?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001932 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Partial Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surgery as a Treatment for Medically Intractable Epilepsy
RECRUITING
-
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
RECRUITING · Phase 3
-
Investigating Epilepsy: Screening and Evaluation
RECRUITING
-
Metabolic Abnormalities in Children With Epilepsy
COMPLETED
-
Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy
COMPLETED
-
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.